Giovanni Faddoul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giovanni Faddoul has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Naoru Koizumi
Schar School of Policy and Government, George Mason University, Fairfax, VA 22030, USA
5 shared publications Jorge Ortiz
Department of Surgery Garnet Health Medical Center Middletown New York USA
4 shared publications- Dayanna Zuluaga
Department of Primary Care, Touro College of Osteopathic Medicine, Middletown, New York, USA
2 shared publications - Emmanuel Albert Aydin‐Ghormoz
Division of Nephrology and Hypertension, Department of Medicine, Albany Medical Center Albany New York USA
2 shared publications - Gavin McAfee
Touro College of Osteopathic Medicine
2 shared publications Mary Ellen Dean
2 shared publications
Latest Publications
- Open Access
Clinical characteristics and associated factors of de novo and recurrent prostate cancer after kidney transplantation
Kidney transplant recipients experience a higher burden of several malignancies, yet the factors associated with prostate cancer presentation after transplantation remain poorly understood. Unlike malignancies strongly associated with impaired immune surveillance, prostate cancer has not consistently demonstrated an increased incidence after transplantation, suggesting that different mechanisms may underlie disease presentation. This study evaluated recipient, donor, transplant, immunologic, and immunosuppressive factors associated with prostate cancer phenotype after kidney transplantation. A retrospective cohort study was conducted using national transplant registry data from adult kidney transplant recipients diagnosed with post-transplant prostate cancer between 2015 and 2024. Cases were classified as de novo (no pre-transplant history of prostate cancer) or recurrent (documented pre-transplant history). Multivariable Firth penalized logistic regression was used to evaluate factors associated with recurrent phenotype. Prespecified sensitivity analyses included deceased donor restricted models, incorporation of donor organ quality variables, and adjustment for time from transplantation to cancer diagnosis. Exploratory machine learning analyses included elastic net logistic regression, random forest, and extreme gradient boosting. The cohort included 660 recipients, of whom 623 (94.4%) had de novo disease and 37 (5.6%) had recurrent disease. Recipient age was the only variable consistently associated with recurrent phenotype across primary and sensitivity analyses (adjusted odds ratio per year 1.11, 95% CI 1.05–1.17; p<0.001). Immunosuppressive regimen, donor characteristics, immunologic variables, and time from transplantation to cancer diagnosis were not independently associated with phenotype in the primary cohort. In deceased donor restricted analyses, alemtuzumab induction showed an exploratory association with recurrent phenotype, although estimates were imprecise. Machine learning models demonstrated modest discrimination and calibration and did not outperform penalized regression approaches. These findings suggest that, among kidney transplant recipients with prostate cancer, differences between recurrent and de novo presentation are more closely associated with recipient age and underlying disease characteristics than with transplant exposures or specific immunosuppressive regimens.
Open AccessClinical characteristics and associated factors of de novo and recurrent prostate cancer after kidney transplantation
Kidney transplant recipients experience a higher burden of several malignancies, yet the factors associated with prostate cancer presentation after transplantation remain poorly understood. Unlike malignancies strongly associated with impaired immune surveillance, prostate cancer has not consistently demonstrated an increased incidence after transplantation, suggesting that different mechanisms may underlie disease presentation. This study evaluated recipient, donor, transplant, immunologic, and immunosuppressive factors associated with prostate cancer phenotype after kidney transplantation. A retrospective cohort study was conducted using national transplant registry data from adult kidney transplant recipients diagnosed with post-transplant prostate cancer between 2015 and 2024. Cases were classified as de novo (no pre-transplant history of prostate cancer) or recurrent (documented pre-transplant history). Multivariable Firth penalized logistic regression was used to evaluate factors associated with recurrent phenotype. Prespecified sensitivity analyses included deceased donor restricted models, incorporation of donor organ quality variables, and adjustment for time from transplantation to cancer diagnosis. Exploratory machine learning analyses included elastic net logistic regression, random forest, and extreme gradient boosting. The cohort included 660 recipients, of whom 623 (94.4%) had de novo disease and 37 (5.6%) had recurrent disease. Recipient age was the only variable consistently associated with recurrent phenotype across primary and sensitivity analyses (adjusted odds ratio per year 1.11, 95% CI 1.05–1.17; p<0.001). Immunosuppressive regimen, donor characteristics, immunologic variables, and time from transplantation to cancer diagnosis were not independently associated with phenotype in the primary cohort. In deceased donor restricted analyses, alemtuzumab induction showed an exploratory association with recurrent phenotype, although estimates were imprecise. Machine learning models demonstrated modest discrimination and calibration and did not outperform penalized regression approaches. These findings suggest that, among kidney transplant recipients with prostate cancer, differences between recurrent and de novo presentation are more closely associated with recipient age and underlying disease characteristics than with transplant exposures or specific immunosuppressive regimens.
- 15 May 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (5) , e70563
Kidney Transplantation for Lithium Nephrotoxicity is Associated With Noninferior Graft and Patient Survival: A National Donor‐Stratified Registry Analysis
Introduction: To evaluate donor‐stratified graft and patient survival following kidney transplantation (KT) for lithium‐associated end‐stage kidney disease (ESKD). Methods: This retrospective analysis utilized the Organ Procurement and Transplantation Network database. Adult KT recipients (January 1, 2015–December 30, 2024) with lithium‐associated nephrotoxicity as the primary listing diagnosis ( n = 840) were compared with those transplanted for other etiologies. Deceased‐donor (DDKT; n = 584) and living‐donor (LDKT; n = 256) cohorts were propensity matched 1:1 within donor type. Gompertz parametric survival models were selected after proportional hazards violation. Results: Median follow‐up was 851 days (DDKT) and 1262 days (LDKT). Matched DDKT recipients with lithium‐associated ESKD had a lower prevalence of body mass index greater than 35 kg/m 2 (16.8% vs. 21.3%, p = 0.047), lower calculated panel reactive antibody (17.45 ± 30.58 vs. 27.85 ± 37.48, p < 0.001) and lower private insurance coverage (20.4% vs. 27.9%, p = 0.003). Lithium toxicity independently predicted reduced graft failure (HR, 0.668; 95% CI, 0.490–0.912; p = 0.011) and mortality (HR, 0.667; 95% CI, 0.483–0.921; p = 0.014). No other covariate retained independent significance in the adjusted model. Lithium‐associated ESKD did not predict graft failure or mortality among LDKT recipients. Conclusion: KT for lithium‐associated ESKD was not associated with inferior outcomes. The favorable survival signal was confined to DDKT. It was more likely attributable to recipient‐level phenotypic differences and donor‐risk context than to any protective property of the underlying diagnosis. Posttransplant lithium dosing, compliance and rechallenge data are not captured in registry data and remain unmeasured.
- 15 May 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (5) , e70563
Kidney Transplantation for Lithium Nephrotoxicity is Associated With Noninferior Graft and Patient Survival: A National Donor‐Stratified Registry Analysis
Introduction: To evaluate donor‐stratified graft and patient survival following kidney transplantation (KT) for lithium‐associated end‐stage kidney disease (ESKD). Methods: This retrospective analysis utilized the Organ Procurement and Transplantation Network database. Adult KT recipients (January 1, 2015–December 30, 2024) with lithium‐associated nephrotoxicity as the primary listing diagnosis ( n = 840) were compared with those transplanted for other etiologies. Deceased‐donor (DDKT; n = 584) and living‐donor (LDKT; n = 256) cohorts were propensity matched 1:1 within donor type. Gompertz parametric survival models were selected after proportional hazards violation. Results: Median follow‐up was 851 days (DDKT) and 1262 days (LDKT). Matched DDKT recipients with lithium‐associated ESKD had a lower prevalence of body mass index greater than 35 kg/m 2 (16.8% vs. 21.3%, p = 0.047), lower calculated panel reactive antibody (17.45 ± 30.58 vs. 27.85 ± 37.48, p < 0.001) and lower private insurance coverage (20.4% vs. 27.9%, p = 0.003). Lithium toxicity independently predicted reduced graft failure (HR, 0.668; 95% CI, 0.490–0.912; p = 0.011) and mortality (HR, 0.667; 95% CI, 0.483–0.921; p = 0.014). No other covariate retained independent significance in the adjusted model. Lithium‐associated ESKD did not predict graft failure or mortality among LDKT recipients. Conclusion: KT for lithium‐associated ESKD was not associated with inferior outcomes. The favorable survival signal was confined to DDKT. It was more likely attributable to recipient‐level phenotypic differences and donor‐risk context than to any protective property of the underlying diagnosis. Posttransplant lithium dosing, compliance and rechallenge data are not captured in registry data and remain unmeasured.
- 8 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (9) , 1-12
Post-nephrectomy outcomes in COVID-19 and non-COVID-19 Patients using ACEi, ARB and SGLT2i: a N3C database study
Purpose Nephrectomy can lead to hyperfiltration, focal segmental glomerulosclerosis (FSGS) and end-stage kidney disease (ESKD). We hypothesize that medications decreasing intraglomerular pressure have a positive impact on glomerular filtration among other outcomes after unilateral nephrectomy. The study investigated the possible impact of the SARS-CoV2 infection known as COVID-19 on outcomes among the unilateral nephrectomy recipients. Methods National Clinical Cohort Collaborative (N3C) database COVID19 Enclave was analyzed using multivariable linear regression and specific outcomes of eGFR values up to 3 years post-nephrectomy, occurrence of ESKD, HTN, FSGS, and gout. Results In the non-COVID19 group, use of ACEi or ARB alone associated with a decrease in eGFR between 1 and 3 years (− 2.71 95% [− 3.90 to − 1.52]; p < 0.001), use of SGLT2i alone correlated with an increase (Coef 5.04 95% [0.781–9.301]; p = 0.02) while the concomitant use of ACEi or ARB with SGLT2i was not related to a variation in eGFR. These associations were not observed in the COVID19 group. COVID19 infection associated with an increased risk of post-nephrectomy ESKD development (HR 1.309 95% [1.066, 1.607]; p = 0.01), FSGS (HR 6.952 95% [2.685, 18.00]; p < 0.001) and gout (HR 1.411 95% [1.043, 1.907]; p = 0.025). Conclusion RAS blockade did not demonstrate any significant impact on the incidence of FSGS. The analysis was limited due to the absence of patients with both SGLT2i use and FSGS. SGLT2 inhibition correlated with an overall beneficial effect on the eGFR trend post-nephrectomy.
- 8 March 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (9) , 1-12
Post-nephrectomy outcomes in COVID-19 and non-COVID-19 Patients using ACEi, ARB and SGLT2i: a N3C database study
Purpose Nephrectomy can lead to hyperfiltration, focal segmental glomerulosclerosis (FSGS) and end-stage kidney disease (ESKD). We hypothesize that medications decreasing intraglomerular pressure have a positive impact on glomerular filtration among other outcomes after unilateral nephrectomy. The study investigated the possible impact of the SARS-CoV2 infection known as COVID-19 on outcomes among the unilateral nephrectomy recipients. Methods National Clinical Cohort Collaborative (N3C) database COVID19 Enclave was analyzed using multivariable linear regression and specific outcomes of eGFR values up to 3 years post-nephrectomy, occurrence of ESKD, HTN, FSGS, and gout. Results In the non-COVID19 group, use of ACEi or ARB alone associated with a decrease in eGFR between 1 and 3 years (− 2.71 95% [− 3.90 to − 1.52]; p < 0.001), use of SGLT2i alone correlated with an increase (Coef 5.04 95% [0.781–9.301]; p = 0.02) while the concomitant use of ACEi or ARB with SGLT2i was not related to a variation in eGFR. These associations were not observed in the COVID19 group. COVID19 infection associated with an increased risk of post-nephrectomy ESKD development (HR 1.309 95% [1.066, 1.607]; p = 0.01), FSGS (HR 6.952 95% [2.685, 18.00]; p < 0.001) and gout (HR 1.411 95% [1.043, 1.907]; p = 0.025). Conclusion RAS blockade did not demonstrate any significant impact on the incidence of FSGS. The analysis was limited due to the absence of patients with both SGLT2i use and FSGS. SGLT2 inhibition correlated with an overall beneficial effect on the eGFR trend post-nephrectomy.
- 20 May 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (4) , e14783
Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens
Background: We hypothesized that alemtuzumab use is safe in pediatric kidney transplant recipients (KTRs) with equivalent long‐term outcomes compared to other induction agents.Methods: Using pediatric kidney transplant recipient data in the UNOS database between January 1, 2000, and June 30, 2022, multivariate logistic regression, multivariable Cox regression, and survival analyses were utilized to estimate the likelihoods of 1st‐year and all‐time hospitalizations, acute rejection, CMV infection, delayed graft function (DGF), graft loss, and patient mortality among recipients of three common induction regimens (ATG, alemtuzumab, and basiliximab).Results: There were no differences in acute rejection or graft failure among induction or maintenance regimens. Basiliximab was associated with lower odds of DGF in deceased donor recipients (OR 0.77 [0.60–0.99], p = .04). Mortality was increased in patients treated with steroid‐containing maintenance (HR 1.3 [1.005–1.7] p = .045). Alemtuzumab induction correlated with less risk of CMV infection than ATG (OR 0.76 [0.59–0.99], p = .039). Steroid‐containing maintenance conferred lower rate of PTLD compared to steroid‐free maintenance (HR 0.59 [0.4–0.8] p = .001). Alemtuzumab was associated with less risk of hospitalization within 1 year (OR 0.79 [0.67–0.95] p = .012) and 5 years (HR 0.54 [0.46–0.65] p < .001) of transplantation. Steroid maintenance also decreased 5 years hospitalization risk (HR 0.78 [0.69–0.89] p < .001).Conclusions: Pediatric KTRs may be safely treated with alemtuzumab induction without increased risk of acute rejection, DGF, graft loss, or patient mortality. The decreased risk of CMV infections and lower hospitalization rates compared to other agents make alemtuzumab an attractive choice for induction in pediatric KTRs, especially in those who cannot tolerate ATG.
- 20 May 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (4) , e14783
Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens
Background: We hypothesized that alemtuzumab use is safe in pediatric kidney transplant recipients (KTRs) with equivalent long‐term outcomes compared to other induction agents.Methods: Using pediatric kidney transplant recipient data in the UNOS database between January 1, 2000, and June 30, 2022, multivariate logistic regression, multivariable Cox regression, and survival analyses were utilized to estimate the likelihoods of 1st‐year and all‐time hospitalizations, acute rejection, CMV infection, delayed graft function (DGF), graft loss, and patient mortality among recipients of three common induction regimens (ATG, alemtuzumab, and basiliximab).Results: There were no differences in acute rejection or graft failure among induction or maintenance regimens. Basiliximab was associated with lower odds of DGF in deceased donor recipients (OR 0.77 [0.60–0.99], p = .04). Mortality was increased in patients treated with steroid‐containing maintenance (HR 1.3 [1.005–1.7] p = .045). Alemtuzumab induction correlated with less risk of CMV infection than ATG (OR 0.76 [0.59–0.99], p = .039). Steroid‐containing maintenance conferred lower rate of PTLD compared to steroid‐free maintenance (HR 0.59 [0.4–0.8] p = .001). Alemtuzumab was associated with less risk of hospitalization within 1 year (OR 0.79 [0.67–0.95] p = .012) and 5 years (HR 0.54 [0.46–0.65] p < .001) of transplantation. Steroid maintenance also decreased 5 years hospitalization risk (HR 0.78 [0.69–0.89] p < .001).Conclusions: Pediatric KTRs may be safely treated with alemtuzumab induction without increased risk of acute rejection, DGF, graft loss, or patient mortality. The decreased risk of CMV infections and lower hospitalization rates compared to other agents make alemtuzumab an attractive choice for induction in pediatric KTRs, especially in those who cannot tolerate ATG.
- 21 December 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15225
Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis
Introduction: IgA nephropathy (IgAN) can cause end‐stage kidney disease (ESKD). This study assesses the impact of induction and maintenance immunosuppression on IgAN recurrence, graft survival, and mortality in living and deceased donor kidney transplants (LDKT and DDKT).Methods: Retrospective analysis of the UNOS database in adults with ESKD secondary to IgAN who received kidney transplants between January 2000 and June 30, 2022. Patients with thymoglobulin (ATG), alemtuzumab, or basiliximab/daclizumab induction with calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) with or without prednisone maintenance were analyzed. Multivariate logistic regression was performed to identify factors correlated with IgA recurrence. Multivariable Cox regression analyses were performed for clinically suspected risk factors. Kaplan Meir Analysis was utilized for overall graft survival.Results: Compared to ATG with steroid maintenance, alemtuzumab with steroid increased the odds of IgAN recurrence in DDKTs (OR 1.90, p < .010, 95% CI [1.169–3.101]). Alemtuzumab with and without steroid increased the odds of recurrence by 52% (p = .036) and 56% (p = .005), respectively, in LDKTs. ATG without steroids was associated with less risk of IgAN recurrence (HR .665, p = .044, 95% CI [.447–.989]), graft failure (HR .758, p = .002, 95% CI [.633–.907]), and death (HR .619, p < .001, 95% CI [.490–.783]) in DDKTs. Recurrence was strongly associated with risks of graft failure in DDKTs and LDKTs and death in LDKTs.Conclusion: In patients with IgAN requiring a kidney transplant, Alemtuzumab induction correlates with increased IgAN recurrence. Relapse significantly affects graft survival and mortality. ATG without steroids is associated with the least graft loss and mortality.
- 21 December 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15225
Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis
Introduction: IgA nephropathy (IgAN) can cause end‐stage kidney disease (ESKD). This study assesses the impact of induction and maintenance immunosuppression on IgAN recurrence, graft survival, and mortality in living and deceased donor kidney transplants (LDKT and DDKT).Methods: Retrospective analysis of the UNOS database in adults with ESKD secondary to IgAN who received kidney transplants between January 2000 and June 30, 2022. Patients with thymoglobulin (ATG), alemtuzumab, or basiliximab/daclizumab induction with calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) with or without prednisone maintenance were analyzed. Multivariate logistic regression was performed to identify factors correlated with IgA recurrence. Multivariable Cox regression analyses were performed for clinically suspected risk factors. Kaplan Meir Analysis was utilized for overall graft survival.Results: Compared to ATG with steroid maintenance, alemtuzumab with steroid increased the odds of IgAN recurrence in DDKTs (OR 1.90, p < .010, 95% CI [1.169–3.101]). Alemtuzumab with and without steroid increased the odds of recurrence by 52% (p = .036) and 56% (p = .005), respectively, in LDKTs. ATG without steroids was associated with less risk of IgAN recurrence (HR .665, p = .044, 95% CI [.447–.989]), graft failure (HR .758, p = .002, 95% CI [.633–.907]), and death (HR .619, p < .001, 95% CI [.490–.783]) in DDKTs. Recurrence was strongly associated with risks of graft failure in DDKTs and LDKTs and death in LDKTs.Conclusion: In patients with IgAN requiring a kidney transplant, Alemtuzumab induction correlates with increased IgAN recurrence. Relapse significantly affects graft survival and mortality. ATG without steroids is associated with the least graft loss and mortality.
- Open Access
- 14 April 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (6) , e851-e860
Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Diabetic kidney disease (DKD) is the leading cause of CKD and ESKD in the United States and worldwide. Pharmacotherapy and lifestyle modifications for glycemia, dyslipidemia, and BP control have shown success in slowing the progression of DKD. Traditional treatments, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and more recently the use of sodium-glucose cotransporter 2 inhibitors, nonsteroidal selective mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide 1 receptor agonists, have led to added benefits on various outcomes. However, significant residual risk for DKD progression remains despite the current standard-of-care approaches. Arteriolar hyalinosis (AH) is among the key findings seen on kidney biopsies of patients with DKD. It results from the excessive accumulation of hyaluronan (HA) in the arterioles. AH has not been targeted specifically by any of the therapeutic methods currently being used. We discuss in this manuscript the potential use of a selective therapy targeting AH and the increased total renal HA deposits using a HA synthesis inhibitor in DKD.
- 14 April 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (6) , e851-e860
Open AccessHyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Diabetic kidney disease (DKD) is the leading cause of CKD and ESKD in the United States and worldwide. Pharmacotherapy and lifestyle modifications for glycemia, dyslipidemia, and BP control have shown success in slowing the progression of DKD. Traditional treatments, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and more recently the use of sodium-glucose cotransporter 2 inhibitors, nonsteroidal selective mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide 1 receptor agonists, have led to added benefits on various outcomes. However, significant residual risk for DKD progression remains despite the current standard-of-care approaches. Arteriolar hyalinosis (AH) is among the key findings seen on kidney biopsies of patients with DKD. It results from the excessive accumulation of hyaluronan (HA) in the arterioles. AH has not been targeted specifically by any of the therapeutic methods currently being used. We discuss in this manuscript the potential use of a selective therapy targeting AH and the increased total renal HA deposits using a HA synthesis inhibitor in DKD.